Sanofi has backed the $75 million series B of a rhinovirus-focused biotech helmed by a former FDA acting commissioner.
Sanofi led a $75 million Series B in Altesa, a rhinovirus antiviral biotech run by a former FDA acting commissioner, to support mid-stage clinical development.
Why it mattersSanofi's $75M Series B in rhinovirus-focused Altesa signals investors to prioritize antiviral portfolio due diligence now.